Introduction
The treatment of patients with cancer in the 21st century has evolved into a complicated algorithm, requiring knowledge of an individual patient's tumor mutation status before initiating therapy. Making mastery of knowledge even more difficult, mutational profiling studies have revealed that within a single type of cancer, even a single gene can harbor multiple different mutations in different individuals. EGF receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) represent a prime example of the complexity of disease at the molecular level. In North America, about 17% of patients with non-small cell lung cancer (NSCLC) harbor EGFR mutations (1), of which approximately 80% to 90% are composed of exon 19 deletions and L858R point mutations (2) , which inherently confer sensitivity to therapy with the EGFR tyrosine kinase inhibitors (TKI), gefitinib or erlotinib (3) . However, there are rare mutations that can be associated with primary drug sensitivity, primary drug resistance, or secondary resistance, while other rarer EGFR mutations are of less clear clinical significance (4) . This rapid evolution of information promises to overwhelm practicing clinicians who will need a mechanism whereby they can quickly and conveniently reference the most accurate therapeutic options for patients with known tumor mutations.
Here, we report on the development of a catalog of clinically relevant somatic mutations, named the DNAmutation Inventory to Refine and Enhance Cancer Treatment (DIRECT). This clinical database is designed to enable a genetically informed approach to cancer medicine by providing clinicians access to tumor gene therapy-response information based on individual patient data published in the literature. As proof-of-principle, we started the catalog on EGFR mutations in lung cancer, aiming to provide a comprehensive database on rare and common mutations associated with disease control and disease progression to EGFR TKI therapy.
Materials and Methods
Searches of the PubMed database from June 2005 to May 2011 were completed to identify relevant studies that reported on EGFR mutations in patients with NSCLCs. The search strategy used the terms Receptor, Epidermal Growth Factor [Mesh] OR (EGFR protein, human [Substance Name]) AND Lung Neoplasms [Mesh] . Additional articles were identified from searching the bibliographies of retrieved articles. An English language restriction was applied. Details of the search strategies are available on request from the authors. All articles were manually reviewed to determine whether the publication met minimum criteria for inclusion by 2 independent reviewers (P. Yeh and J. Andrews). Additional articles were identified from searching the bibliographies of retrieved articles. The review of articles was conducted manually as most of the individual patient-level data, if presented, was within a table or image form, undetectable by automated, computerized methods. After the cutoff date for the PubMed search query, a retrospective search on the database was conducted to identify duplicate patient data published in multiple studies. The database was further verified by having 2 independent investigators (L. Horn and W. Pao) recheck at least every tenth patient data entry with the primary source reference. Any discrepancies were resolved through collective agreement.
All data was entered into an open source, electronic data capture program, the Research Electronic Data Capture (REDCap) project, from Vanderbilt University (Nashville, TN; refs. 5, 6) . Only articles with individual patient data that provided the minimum following criterion were included: EGFR mutation, type of systemic treatment, and associated outcome including response rate (RR), progression-free survival (PFS), and/or overall survival (OS). At this time, only patients treated with the EGFR TKIs, gefitinib and erlotinib, were included. Data from studies with secondgeneration EGFR TKIs, such as afatinib (BIBW2992), neratinib (HKI-272), dacomitinib (PF-00299804), and XL647, will be included in future studies.
Response rate was classified into two categories, disease control and disease progression. Disease control was used to describe patients who achieved a complete response (CR), partial response (PR), or stable disease (SD), as defined by Response Evaluation Criteria in Solid Tumors (RECIST; ref. 7) , following treatment with gefitinib or erlotinib. Disease progression was categorized as patients who had progressive disease (PD) as defined by the RECIST (7) following treatment with gefitinib or erlotinib. If a particular mutation had patients in both groups, that particular mutation was classified in the disease control or disease progression group based on whatever group had the higher percentage of a particular response. Additional data included if available were patient age, gender, ethnicity, smoking status, tumor histology, cancer stage at diagnosis, Eastern Cooperative Oncology Group (ECOG) performance status, and number of prior therapies. The PubMed ID, primary author name, journal name, and year of publication were recorded for each individual patient. Patients with acquired resistance to EGFR TKI therapy were catalogued separately (n ¼ 61 from 9 different studies) from those with de novo mutations (i.e., disease previously untreated with EGFR TKIs).
Descriptive statistics, including medians, and ranges of continuous variables, as well as percentages and frequencies for categorical variables, were tabulated. The demographic analysis of the final DIRECT patient pool for this article was conducted using R Statistical Computing Program Version 14Á1 (8) .
Results
The initial search identified 2085 publications including prospective studies, retrospective studies, and case reports (Fig. 1) . Of the 2085 publications, 1,939 articles were excluded for not meeting minimum inclusion criteria. The most common reason for exclusion was data presented in an aggregate population form such as a clinical trial. Of the 2085 publications, 146 papers met minimum criterion for inclusion into the DIRECT database. The number of therapy-response entries exceeds the number of individual patient entries, as some patient reports included more than one line of treatment.
After filtering out patients treated with only with other therapies (e.g., chemotherapy regimens), 1,149 patients with a total of 1,207 unique therapy-response entries still remained. Forty-two patients (with 47 therapy-response entries) were excluded because the exact EGFR mutation was unreported, and 79 patients (with 83 therapy-response entries) were excluded because the responses to EGFR TKI
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The median age of patients was 62 years ( Table 1 ). The majority of the DIRECT patients with reported clinical features was female (42.8% vs. 28.0% male), Asian (66.6% vs. 18.5% Caucasian), never smokers (42.4% vs. 26.5% current/former smokers) with adenocarcinoma histology (65.8% vs. 24.8% other histology). About 63.6% had stage IIIB/IV or IV lung cancer (32.5% had unrecorded cancer staging). A significant portion of the patient pool had unknown demographic features ( Table 1) .
The mutations from each of the 1,021 patients were then classified into mutations associated with disease control, disease progression, or acquired resistance (Supplementary  Table S1, Tables 2 and 3) . Several mutations had patients that fit more than one category. For example, 2 of 3 patients with L861R mutation had disease control with EGFR TKI treatment; L861R was classified as a mutation with EGFR TKI disease control. Five mutation combinations that had a perfectly even split between 2 groups were classified as mutations associated with disease control because half of the patient sample achieved a SD, PR, or CR response, indicating the mutation seems at least somewhat sensitive to EGFR TKI therapy.
We identified more than 188 unique EGFR mutations, occurring in 207 different combinations. For example, some patients had either L858R alone (n ¼ 225 from 62 studies), T790M alone (n ¼ 6 from 3 studies), or both L858R and T790M in combination (n ¼ 27 from 11 studies), resulting in an analysis of just 2 unique mutations (L858R and T790M) but 3 different noted mutation combinations. Of the 207 EGFR mutation combinations, 149 (72.0%) met criteria for disease control, 42 (20.3%) were 
L858R
About 210 of the 235 therapy-response instances (89%) from 225 patients with a single L858R mutation achieved disease control with either gefitinib or erlotinib. L858R mutations were also frequently found with a second de novo mutation (n ¼ 31). Including all combinations of L858R mutation with concurrent de novo mutations, 237 of the 266 therapy-response instances (89%) from 256 unique patients achieved disease control. L858R mutations occurring in combination with either A871E, L747S, de novo G719S, de novo T790M, L861P, or R776G were associated with disease progression.
Del19
A total of 191 of the 215 therapy-response instances (89%) from 204 separate patients with a single del19 E746-A750 mutation achieved disease control. Including patients with del19 E746-A750 mutation and a concurrent de novo mutation, 201 of the >225 therapy-response instances (89%) from 213 separate patients achieved disease control. Factoring in all patients from the 53 mutation combinations involving a del19 mutation, including those with an unspecified amino acid deletion in exon 19 (del19 unspecified) and those with concurrent de novo mutation(s), 424 of the 466 therapy-response instances (91%) from 439 patients were classified as having disease control. Del19 unspecified in combination with either ins20 unspecified or V769M were noted to be associated with disease progression. Only one patient with each combination was in DIRECT, making any determination of their therapeutic significance difficult.
G719X
Fourteen of 18 therapy-responses and 18 patients (78%) with a single G719X mutation-G719A, G719C, G719D, and G719S-achieved disease control. Expanding the pool to all patients with a G719X and concurrent de novo Number of unique studies refers to the number of different studies that encompass all of the patients with a particular mutation in DIRECT. 
L861Q
Twelve of 14 therapy-response instances (86%) from 13 patients with a single L861Q mutation achieved disease control. Including all patients with L861Q and concurrent de novo mutations, 17 of 19 therapy-response instances (89%) from 18 patients had disease control. However, only 7 of these 17 (41%) disease control therapy-responses were partial responses; the other 10 met stable disease criteria. In contrast, 177 of the 237 disease control therapy-responses (75%) for L858R, 332 of the 424 disease control therapyresponses (78%) for del19, and 16 of the 20 disease control therapy-responses (80%) for G719X were partial responses, suggesting that L858R, exon 19 deletion, and G719X mutations respond more favorably to gefitinib or erlotinib than L861Q.
T790M
Both therapy-responses from 2 patients in DIRECT with a de novo T790M mutation had progressive disease. Five of 6 therapy-response instances (83%) and 6 patients with de novo L858R þ T790M had disease progression.
Acquired resistance
Fifty-seven of 60 patients (95%) with acquired resistance to EGFR TKI therapy had T790M. The other 3 patients developed a D761Y, L747S, or T854A resistance mutation, in line with known acquired resistance mutations to EGFR TKI therapy (9) . Other resistance mechanisms (e.g., MET amplification, PIK3CA mutation, etc.) were outside the focus of this current report but will be included in future studies. Del19 E746-A750 was found with T790M acquired resistance mutation in 14 patients from 5 studies, whereas the L858R mutation was found with acquired resistance mutation T790M in 21 patients from 6 studies.
Discussion
The DIRECT database represents the most comprehensive catalog of EGFR mutations and response to gefitinib or erlotinib therapy to date. The majority of the mutations in the DIRECT database are rare mutations with limited clinical data that may not be readily accessible to the busy clinician. As expected for more common mutations, L858R and exon 19 deletions were associated with disease control, whereas the T790M mutation was associated with disease progression on an EGFR TKI. We further confirm that G719X and L861Q mutations confer sensitivity to EGFR TKIs, although L861Q mutations were associated with a lower response rate. As an increasing number of patients have their tumors genotyped, there will be (and is already) a dire need for an interactive easily accessible educational tool that provides up-to-date information to physicians on the clinical relevance of mutations in cancers. The database is currently available for (10) . Since its inception, we have averaged 5 to 6 queries per month from around the world, the majority (>80%) for rare mutations. The number of queries continues to increase monthly. With time and with proper data sharing agreements for data from large clinical trials, we intend to change this into an interactive platform that will provide immediate data at the point of care to aid in therapeutic decisions. Currently, DIRECT catalogs only patients with NSCLCs and published individual patient data on EGFR mutations. We are working with collaborators to expand the database to include individual patient data from large randomized phase II and III trials on patients with EGFR mutations and response to EGFR TKIs and chemotherapy. We also plan to incorporate other known mutations in solid tumors (e.g. melanoma, gastrointestinal stromal tumors, etc.) for which mutation-response data exist. To truly realize the promise of personalized medicine, all publications involving genotype-driven trials should at a minimum publish Supplementary Tables listing individual patients by tumor mutation status and treatment outcome.
This study has several limitations. First, not all demographic data including gender, smoking status, tumor histology, and stage were available for inclusion. These data do not affect the reported mutation-response data but do not allow classification of specific mutations within demographic categories. Second, of our 207 mutation combinations, 67% or 138 mutation combinations (97 disease control, 33 disease progressing, and 8 acquired resistance) are rare mutations for which there are only data from one patient, making any determination of their therapeutic significance difficult. Finally, we did not record the specific method of EGFR mutation testing from each study and thus this article does not take into account the variance in EGFR mutation detection between differing studies. Nevertheless, these data may serve as an initial guide in selecting therapy. As more and more patients have their tumors genotyped, the number of patients with such "rare mutations" will grow and their clinical significance will emerge.
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